Get started
Author

Courtney L. Erskine

Observed names: C. Erskine, Courtney L. Erskine, Courtney Erskine, Courtney L Erskine, Erskine, Courtney L
Institution: Mayo Clinic
Observed institutions: Mayo Clinic, University of Pittsburgh, Purdue University West Lafayette, UPMC Hillman Cancer Center, Children's Hospital of Pittsburgh, Mayo Clinic in Florida, Mayo Clinic Comprehensive Cancer Center (Minnesota), Mayo Clinic Comprehensive Cancer Center (Florida), University of Rochester
ORCID: 0000-0001-8873-1542
Observed ORCID: 0000-0001-8873-1542
OpenAlex ID: A5065454745
Tumor-Infiltrating Programmed Death Receptor-1+ Dendritic Cells Mediate Immune Suppression in Ovarian Cancer
2011 · James Krempski, Lavakumar Karyampudi, et al. · The Journal of Immunology · 251
PDF
Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma
2018 · Aaron S. Mansfield, Tobias Peikert, et al. · Journal of Thoracic Oncology · 129
PDF
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial
2010 · Håkan Norell, Isabel Poschke, et al. · Journal of Translational Medicine · 124
PDF
Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients
2018 · Kimberly R. Kalli, Matthew S. Block, et al. · Clinical Cancer Research · 102
Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients
2020 · Matthew S. Block, Allan B. Dietz, et al. · Nature Communications · 89
PDF
The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity
2007 · Marshall D. Behrens, Wolfgang M. Wagner, et al. · Blood · 84
PDF
T-Cell Immunity to the Folate Receptor Alpha Is Prevalent in Women With Breast or Ovarian Cancer
2006 · Keith L. Knutson, Christopher J. Krco, et al. · Journal of Clinical Oncology · 75
Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain
2016 · Keith L. Knutson, Raphael Clynes, et al. · Cancer Research · 59
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial
2020 · Dmitriy Zamarin, Sven Walderich, et al. · Journal for ImmunoTherapy of Cancer · 57
Risk assessment of latent tuberculosis infection through a multiplexed cytokine biosensor assay and machine learning feature selection
2021 · Heather M. Robison, Cole A. Chapman, et al. · Scientific Reports · 37
PDF
Determining Optimal Cytotoxic Activity of Human Her2neu Specific CD8 T cells by Comparing the Cr51 Release Assay to the xCELLigence System
2012 · Courtney L. Erskine, Andrea M. Henle, et al. · Journal of Visualized Experiments · 37
Utility of Progranulin and Serum Leukocyte Protease Inhibitor as Diagnostic and Prognostic Biomarkers in Ovarian Cancer
2013 · Aaron M. Carlson, Matthew J. Maurer, et al. · Cancer Epidemiology Biomarkers & Prevention · 35
Combinatorial Immunoprofiling in Latent Tuberculosis Infection. Toward Better Risk Stratification
2015 · Patricio Escalante, Tobias Peikert, et al. · American Journal of Respiratory and Critical Care Medicine · 33
Plasma immune analytes in patients with epithelial ovarian cancer
2015 · Matthew S. Block, Matthew J. Maurer, et al. · Cytokine · 33
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial
2024 · Tina J. Hieken, Garth D. Nelson, et al. · Nature Communications · 29
PDF
Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy
2022 · Paige K. Marty, Virginia P. Van Keulen, et al. · Frontiers in Immunology · 26
PDF
Precision immunoprofiling to reveal diagnostic signatures for latent tuberculosis infection and reactivation risk stratification
2019 · Heather M Robison, Patricio Escalante, et al. · Integrative Biology · 20
Determining Optimal Cytotoxic Activity of Human Her2neu Specific CD8 T cells by Comparing the Cr51 Release Assay to the xCELLigence System
2012 · Courtney L. Erskine, Andrea M. Henle, et al. · Journal of Visualized Experiments · 20
PDF
Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine
2019 · Keith L. Knutson, Matthew S. Block, et al. · Clinical Cancer Research · 19
An HLA-DR–Degenerate Epitope Pool Detects Insulin-like Growth Factor Binding Protein 2–Specific Immunity in Patients with Cancer
2008 · Kimberly R. Kalli, Christopher J. Krco, et al. · Cancer Research · 18
PDF
MHC Class II Epitope Nesting Modulates Dendritic Cell Function and Improves Generation of Antigen-Specific CD4 Helper T Cells
2011 · Courtney L Erskine, Christopher J Krco, et al. · The Journal of Immunology · 16
PDF
PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction
2023 · Upasana Ray, Prabhu Thirusangu, et al. · Oncogene · 15
PDF
Comparison of replicating and nonreplicating vaccines against SARS-CoV-2
2022 · Haley E. Mudrick, Shane Massey, et al. · Science Advances · 15
Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer
2018 · Nadine Norton, Nicholas Fox, et al. · Breast Cancer Research · 15
PDF
A Degenerate HLA-DR Epitope Pool of HER-2/neu Reveals a NovelIn vivoImmunodominant Epitope, HER-2/neu88-102
2010 · Lavakumar Karyampudi, Courtney Formicola, et al. · Clinical Cancer Research · 15
Works count: 88
Citation count: 1,476
H-index: 19
I10-index: 28
Year
Topic
Type